While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. That said, here are two cash-producing companies that leverage their financial strength to beat the competition and one that may face some trouble.
One Stock to Sell:
PVH (PVH)
Trailing 12-Month Free Cash Flow Margin: 8%
Founded in 1881 by a husband and wife duo, PVH (NYSE: PVH) is a global fashion conglomerate with iconic brands like Calvin Klein and Tommy Hilfiger.
Why Are We Out on PVH?
- Underwhelming constant currency revenue performance over the past two years suggests its product offering at current prices doesn’t resonate with customers
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- ROIC hasn’t moved, making investors question whether its recent investments can increase profitability
PVH’s stock price of $73.53 implies a valuation ratio of 6.4x forward P/E. Check out our free in-depth research report to learn more about why PVH doesn’t pass our bar.
Two Stocks to Watch:
Uber (UBER)
Trailing 12-Month Free Cash Flow Margin: 18.3%
Notoriously funded with $7.7 billion from the Softbank Vision Fund, Uber (NYSE: UBER) operates a platform of on-demand services such as ride-hailing, food delivery, and freight.
Why Are We Bullish on UBER?
- Monthly Active Platform Consumers have grown by 15.6% annually, allowing for more profitable cross-selling opportunities if it can build complementary products and features
- Performance over the past three years was turbocharged by share buybacks, which enabled its earnings per share to grow faster than its revenue
- Free cash flow margin increased by 13.3 percentage points over the last few years, giving the company more capital to invest or return to shareholders
Uber is trading at $71.04 per share, or 12.1x forward EV/EBITDA. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free.
ANI Pharmaceuticals (ANIP)
Trailing 12-Month Free Cash Flow Margin: 17.7%
With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.
Why Are We Positive on ANIP?
- Market share has increased this cycle as its 34.7% annual revenue growth over the last two years was exceptional
- Earnings growth has massively outpaced its peers over the last five years as its EPS has compounded at 19.9% annually
- Free cash flow margin grew by 38.5 percentage points over the last five years, giving the company more chips to play with
At $75.33 per share, ANI Pharmaceuticals trades at 7.8x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
